IVI-RMA Global
→
KKR
Acquisition · Cash (leveraged buyout) · announced Mar 1, 2022
Announced
Mar 1, 2022
Closed
Jan 18, 2023
Economics
Cash (leveraged buyout)()
Pre-deal · pre-deal mark: 2022, year precision · rounding grid ±$100M · KKR press release — IVI-RMA Global acquisition, 2023
~€3B ($3.25B) for 80% stake; world's largest fertility clinic acquisition; founders retained 20%
Target
IVI-RMA Global
Fertility · Fertility science
HQ Valencia, Spain · Founded 1990
World's largest fertility clinic network; 75+ clinics and 28 labs in 9 countries; formed from 2017 merger of Spain's IVI and US-based RMANJ
- Axios Pro (April 13, 2022) - deal announcement
- Fertility Bridge (January 26, 2023) - deal close confirmation
- Spanish CNMC regulatory approval (December 21, 2022)
Acquirer
KKR
Healthcare
HQ New York, NY
Global investment firm; major investor in fertility clinic consolidation
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Created world's largest fertility services group by combining IVI-RMA with KKR's prior GeneraLife acquisition; 75+ clinics in 9 countries
Evidence ladder
Tertiary (trade / analyst)
Axios Pro (April 13, 2022)
Tertiary (trade / analyst)
Fertility Bridge (January 26, 2023)
Tertiary (trade / analyst)
CNMC approval (December 21, 2022)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- ~€3B ($3.25B) for 80% stake; world's largest fertility clinic acquisition; founders retained 20%
- Pre-deal valuation sourced from: KKR press release — IVI-RMA Global acquisition, 2023. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Fertility
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Fertility deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| Indira IVF | BPEA EQT | Jul 28, 2023 | ||
| Eugin Group (North American operations) | KKR (via IVI-RMA) | Nov 1, 2023 | ||
| Hamilton Thorne | Astorg | Jul 22, 2024 | ||
| Modern Fertility | Ro | May 19, 2021 |
Other verified deals by KKR
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by KKR are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — IVI-RMA Global (Fertility). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.